Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost ...

Scalable collaboration for biotech and pharma teams: Enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing Integrated, AI-ready biologics ecosystem: Connects ...

Revvity, Inc. RVTY recently introduced Signals Xynthetica, a next-generation AI-augmented design platform aimed at transforming molecular and materials discovery across scientific industries.

Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering Lilly TuneLab was established to make advanced AI/ML models, trained on ...

Acquisition deepens Revvity Signals’ presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions ACD/Labs brings deep expertise in supporting ...

Calyxia streamlined its workflows with Revvity Signals, speeding up IP development and enabling a smoother transition from ...

Unified data workflows help specialty chemical teams improve efficiency, reduce risks, and bring products to market faster.

Revvity, Inc. RVTY announced the launch of Signals BioDesign, a cloud-based molecular cloning platform, under its Revvity Signals Software division. Designed for biotech and pharmaceutical R&D teams, ...

Enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing Integrated, AI-ready biologics ecosystem: Connects design to execution through native Signals One ...